“These results support data from previous studies,” says lead author of the study, Gerd R. Burmester, MD, professor of medicine and director of the Department of Rheumatology and Clinical Immunology, Charité-University Medicine Berlin, Germany.
Unique to this study was the use of multiple pulmonary function tests to provide a longitudinal, long-term assessment of pulmonary function. A particularly important finding was that no pulmonary deterioration occurred with long-term use of mavrilimumab. Identifying long-term effects of mavrilimumab on pulmonary function is particularly important given the potential harmful effects of blocking GM-CSF, which plays a critical role in lung homeostasis and promoting alveolar macrophage development.
A particularly important finding was that no pulmonary deterioration occurred with long-term use of mavrilimumab.